Wall Street Associates’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Wall Street Associates’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-460,000	Closed	-$4.16M	–	363
2013 Q4	$4.16M	Hold	460,000	–	–	0.34%	108
2013 Q3	$2.9M	Hold	460,000	–	–	0.27%	122
2013 Q2	$3.14M	Buy	+460,000	New	+$3.2M	0.32%	105

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wall Street Associates's CADX Position: Q1 2014 in Review

Wall Street Associates sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 460,000 shares — an estimated $4.16M sold.

Wall Street Associates first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $4.16M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

Wall Street Associates reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
Wall Street Associates sold 460,000 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $4.16M.
Wall Street Associates first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
Wall Street Associates's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $4.16M in Q4 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Wall Street Associates's 13F filing for Q1 2014, filed 13 May 2014.